Oxygen Biotherapeutics (OXBT) 4.04 $OXBT
Tenax Therapeutics Announces First Quarter Fiscal Year 2015 Financial Results
Business Wire - Wed Sep 24, 7:00AM CDT
--- Initiated and enrolled first patients in Phase 3 LEVO-CTS trial for levosimendan in LCOS in the U.S., with data expected in first calendar quarter of 2016 -
TENX: 3.22 (-0.01), OXBT: 4.04 (+0.02)
Oxygen Biotherapeutics discloses change in name and ticker symbol
M2 - Wed Sep 17, 5:17AM CDT
Specialist pharmaceutical company Oxygen Biotherapeutics (NasdaqCM:OXBT) reported on Monday the receipt of shareholder's approval to change its name to Tenax Therapeutics with effect from 19 September 2014.
OXBT: 4.04 (+0.02)
Oxygen Biotherapeutics Announces Name Change to Tenax Therapeutics (NASDAQ: TENX)
Business Wire - Tue Sep 16, 7:30AM CDT
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced that the Company received shareholder approval to change the Company name to Tenax Therapeutics, Inc. The name change shall go into effect on Friday, September 19, 2014, and at market open the Company's common stock will trade on the NASDAQ Capital Market under its new ticker symbol "TENX".
OXBT: 4.04 (+0.02)
Oxygen Biotherapeutics Announces Halt of Oxycyte Phase IIb Traumatic Brain Injury Trial
Business Wire - Thu Sep 11, 4:30PM CDT
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced that the Company, with unanimous approval from the Board of Directors, has elected to stop the current Phase IIb trial for its Oxycyte drug candidate and consider strategic alternatives for the program moving forward. The company will review the data generated on the patients enrolled in the trial to date.
OXBT: 4.04 (+0.02)
Oxygen Biotherapeutics to Present at Wedbush 2014 Life Sciences Management Access Conference
Business Wire - Thu Aug 07, 3:00PM CDT
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today that John Kelley, Chief Executive Officer, will present a company overview at the Wedbush 2014 Life Sciences Management Access Conference at Le Parker Meridien in New York on Wednesday, August 13, 2014, at 1:20 p.m. ET.
OXBT: 4.04 (+0.02)
Oxygen Biotherapeutics Announces Collaboration with Imperial College London to Accelerate Enrollment of LeoPARDS Trial
Business Wire - Wed Aug 06, 7:00AM CDT
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced a collaboration with Imperial College London to provide supplemental funding to support the accelerated enrollment and completion of the ongoing LeoPARDS Trial (Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis) awarded by the Efficacy and Mechanism Evaluation (EME) Programme and funded by the Medical Research Council (MRC) and managed by the National Institute for Health Research (NIHR) on behalf of the MRC-NIHR partnership. Oxygen is also currently preparing to initiate a Phase 3 trial in the United States during the third quarter to evaluate levosimendan in cardiac surgery patients at risk of developing low cardiac output syndrome (LCOS).
OXBT: 4.04 (+0.02)
Oxygen Biotherapeutics Announces Fiscal Year 2014 Financial Results
Business Wire - Tue Jul 29, 7:01AM CDT
--Activated sites for Phase 3 LEVO-CTS trial for levosimendan in LCOS in the U.S., with data expected in first calendar quarter of 2016
OXBT: 4.04 (+0.02)
Oxygen Biotherapeutics to Announce Fourth Quarter and Fiscal Year 2014 Financial Results on July 29, 2014
Business Wire - Tue Jul 22, 7:32PM CDT
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today that the Company will host a conference call and live audio webcast on Tuesday, July 29, 2014, at 8:30 a.m. ET to report financial results for the fourth quarter and fiscal year ended April 30, 2014, and provide a corporate update.
OXBT: 4.04 (+0.02)
Recent Scientific Publications Highlight Potential Benefits of Levosimendan in Cardiac Surgery and Additional Critical Care Conditions
Business Wire - Wed Jul 09, 7:30AM CDT
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today highlighted three recent review articles examining the current clinical use of levosimendan and its potential to address a wide range of critical care conditions.
OXBT: 4.04 (+0.02)
Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products to 2017
M2 - Mon Jun 30, 2:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/45fldn/blood_the) has announced the addition of the "Blood: The Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products" report to their offering. The Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products provides an analysis of all the key market segments involved in this industry, including products, equipment and testing. The global blood industry has experienced strong growth in recent years and although this brisk expansion will slow somewhat as products continue to mature and pricing pressures increase, growth will remain solid though 2017 as a result of aging populations in the U.S., Europe and Japan; ongoing technology advancements/new product introductions and indications; expansion of health coverage in the U.S. via health care reform; and continued strong promotion of blood donation by collection agencies. A variety of infectious agents can be present in blood, including viruses (e.g., HIV-1, hepatitis B and C, HTLV, West Nile virus), bacteria, protozoans, Chagas disease, Lyme Disease and prions (e.g., the agent of variant Crueutzfeldt-Jakob disease, which is the human form of mad cow disease). As of 2013, the main residual risk is due to hepatitis B virus - ranging from 10 in Spain to 1.6 per million donations in France and Germany although other conditions such as variant Creutzfeldt-Jakob disease (vCJD) or HIV may pose high risk in certain regions. Testing markets covered include: - Blood Banking and Plasmapheresis Testing - Blood Typing - Human Immunodeficiency Virus (HIV) Testing - Hepatitis A Virus Testing - Hepatitis B Virus Testing - Hepatitis C Virus Testing - Human T-Cell Leukemia Virus Testing - West Nile Virus Testing - Other Safety Testing Blood products covered in the report include: - Red Blood Cells (RBCs) - Immunoglobulins - Albumin - Other Plasma Products - Synthetic HBOC and PFC Agents - Recombinant Factors Blood equipment revenues and forecasts are provided for: - Blood Collection Equipment - Automated Blood Collection Equipment In addition to complete market data, including forecasts to 2017, the study reports: - Product demand estimates by region - Collection and transfusion estimates - High-blood-loss procedure estimates - Product pricing - Reimbursement rates - Epidemiology of key conditions requiring blood products - Products on the market and in development The report also profiles key companies in the industry, including: - AABB - Abbott Laboratories - America's Blood Centers - American Red Cross - Baxter International - Bio-Rad Laboratories - BioTime Inc. - Gen-Probe Inc. /Hologic - Fenwal/Fresenius Kabi - Grifols Biologicals, Inc. - Novartis Diagnostics - Novo Nordisk A/S - OPK BioTech - Oxygen Biotherapeutics - Perftoran - Roche - Sanguine Corp. For more information visit http://www.researchandmarkets.com/research/45fldn/blood_the
ABT: 46.09 (+0.87), OXBT: 4.04 (+0.02), NVO: 43.76 (+0.61), BAX: 70.39 (+0.31), HOLX: 30.46 (+0.21), NVS: 102.20 (-0.17)
Oxygen Biotherapeutics Inc. Provides an Update on Communication with the FDA Regarding Oxycyte Development Program
Business Wire - Tue Mar 04, 7:01AM CST
Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today that it has been notified by the U.S. Food and Drug Administration (the "FDA"
that the agency has completed its review of the September 2013 nonclinical submission and has lifted the clinical hold on Oxycyte(R). Lifting of the clinical hold clears the company to proceed with the clinical development program in the US. The FDA communicated this information to the company during a conference call with the FDA on Friday, February 28, 2014. Written confirmation of the FDA's decision is expected to be received within 30 days.
OXBT: 4.04 (+0.02), EMCI: 33.30 (-0.55)
Research and Markets: Panel Builders Market: Research & Analysis UK 2014-2018
Business Wire - Thu Feb 20, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/5b4nzh/panel_builders) has announced the addition of the "Panel Builders Market: Research & Analysis UK 2014-2018" report to their offering.
OXBT: 4.04 (+0.02)
Tenax Therapeutics Announces First Quarter Fiscal Year 2015 Financial Results
Business Wire - Wed Sep 24, 7:00AM CDT
--- Initiated and enrolled first patients in Phase 3 LEVO-CTS trial for levosimendan in LCOS in the U.S., with data expected in first calendar quarter of 2016 -
TENX: 3.22 (-0.01), OXBT: 4.04 (+0.02)
Oxygen Biotherapeutics discloses change in name and ticker symbol
M2 - Wed Sep 17, 5:17AM CDT
Specialist pharmaceutical company Oxygen Biotherapeutics (NasdaqCM:OXBT) reported on Monday the receipt of shareholder's approval to change its name to Tenax Therapeutics with effect from 19 September 2014.
OXBT: 4.04 (+0.02)
Oxygen Biotherapeutics Announces Name Change to Tenax Therapeutics (NASDAQ: TENX)
Business Wire - Tue Sep 16, 7:30AM CDT
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced that the Company received shareholder approval to change the Company name to Tenax Therapeutics, Inc. The name change shall go into effect on Friday, September 19, 2014, and at market open the Company's common stock will trade on the NASDAQ Capital Market under its new ticker symbol "TENX".
OXBT: 4.04 (+0.02)
Oxygen Biotherapeutics Announces Halt of Oxycyte Phase IIb Traumatic Brain Injury Trial
Business Wire - Thu Sep 11, 4:30PM CDT
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced that the Company, with unanimous approval from the Board of Directors, has elected to stop the current Phase IIb trial for its Oxycyte drug candidate and consider strategic alternatives for the program moving forward. The company will review the data generated on the patients enrolled in the trial to date.
OXBT: 4.04 (+0.02)
Oxygen Biotherapeutics to Present at Wedbush 2014 Life Sciences Management Access Conference
Business Wire - Thu Aug 07, 3:00PM CDT
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today that John Kelley, Chief Executive Officer, will present a company overview at the Wedbush 2014 Life Sciences Management Access Conference at Le Parker Meridien in New York on Wednesday, August 13, 2014, at 1:20 p.m. ET.
OXBT: 4.04 (+0.02)
Oxygen Biotherapeutics Announces Collaboration with Imperial College London to Accelerate Enrollment of LeoPARDS Trial
Business Wire - Wed Aug 06, 7:00AM CDT
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced a collaboration with Imperial College London to provide supplemental funding to support the accelerated enrollment and completion of the ongoing LeoPARDS Trial (Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis) awarded by the Efficacy and Mechanism Evaluation (EME) Programme and funded by the Medical Research Council (MRC) and managed by the National Institute for Health Research (NIHR) on behalf of the MRC-NIHR partnership. Oxygen is also currently preparing to initiate a Phase 3 trial in the United States during the third quarter to evaluate levosimendan in cardiac surgery patients at risk of developing low cardiac output syndrome (LCOS).
OXBT: 4.04 (+0.02)
Oxygen Biotherapeutics Announces Fiscal Year 2014 Financial Results
Business Wire - Tue Jul 29, 7:01AM CDT
--Activated sites for Phase 3 LEVO-CTS trial for levosimendan in LCOS in the U.S., with data expected in first calendar quarter of 2016
OXBT: 4.04 (+0.02)
Oxygen Biotherapeutics to Announce Fourth Quarter and Fiscal Year 2014 Financial Results on July 29, 2014
Business Wire - Tue Jul 22, 7:32PM CDT
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today that the Company will host a conference call and live audio webcast on Tuesday, July 29, 2014, at 8:30 a.m. ET to report financial results for the fourth quarter and fiscal year ended April 30, 2014, and provide a corporate update.
OXBT: 4.04 (+0.02)
Recent Scientific Publications Highlight Potential Benefits of Levosimendan in Cardiac Surgery and Additional Critical Care Conditions
Business Wire - Wed Jul 09, 7:30AM CDT
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today highlighted three recent review articles examining the current clinical use of levosimendan and its potential to address a wide range of critical care conditions.
OXBT: 4.04 (+0.02)
Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products to 2017
M2 - Mon Jun 30, 2:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/45fldn/blood_the) has announced the addition of the "Blood: The Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products" report to their offering. The Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products provides an analysis of all the key market segments involved in this industry, including products, equipment and testing. The global blood industry has experienced strong growth in recent years and although this brisk expansion will slow somewhat as products continue to mature and pricing pressures increase, growth will remain solid though 2017 as a result of aging populations in the U.S., Europe and Japan; ongoing technology advancements/new product introductions and indications; expansion of health coverage in the U.S. via health care reform; and continued strong promotion of blood donation by collection agencies. A variety of infectious agents can be present in blood, including viruses (e.g., HIV-1, hepatitis B and C, HTLV, West Nile virus), bacteria, protozoans, Chagas disease, Lyme Disease and prions (e.g., the agent of variant Crueutzfeldt-Jakob disease, which is the human form of mad cow disease). As of 2013, the main residual risk is due to hepatitis B virus - ranging from 10 in Spain to 1.6 per million donations in France and Germany although other conditions such as variant Creutzfeldt-Jakob disease (vCJD) or HIV may pose high risk in certain regions. Testing markets covered include: - Blood Banking and Plasmapheresis Testing - Blood Typing - Human Immunodeficiency Virus (HIV) Testing - Hepatitis A Virus Testing - Hepatitis B Virus Testing - Hepatitis C Virus Testing - Human T-Cell Leukemia Virus Testing - West Nile Virus Testing - Other Safety Testing Blood products covered in the report include: - Red Blood Cells (RBCs) - Immunoglobulins - Albumin - Other Plasma Products - Synthetic HBOC and PFC Agents - Recombinant Factors Blood equipment revenues and forecasts are provided for: - Blood Collection Equipment - Automated Blood Collection Equipment In addition to complete market data, including forecasts to 2017, the study reports: - Product demand estimates by region - Collection and transfusion estimates - High-blood-loss procedure estimates - Product pricing - Reimbursement rates - Epidemiology of key conditions requiring blood products - Products on the market and in development The report also profiles key companies in the industry, including: - AABB - Abbott Laboratories - America's Blood Centers - American Red Cross - Baxter International - Bio-Rad Laboratories - BioTime Inc. - Gen-Probe Inc. /Hologic - Fenwal/Fresenius Kabi - Grifols Biologicals, Inc. - Novartis Diagnostics - Novo Nordisk A/S - OPK BioTech - Oxygen Biotherapeutics - Perftoran - Roche - Sanguine Corp. For more information visit http://www.researchandmarkets.com/research/45fldn/blood_the
ABT: 46.09 (+0.87), OXBT: 4.04 (+0.02), NVO: 43.76 (+0.61), BAX: 70.39 (+0.31), HOLX: 30.46 (+0.21), NVS: 102.20 (-0.17)
Oxygen Biotherapeutics Inc. Provides an Update on Communication with the FDA Regarding Oxycyte Development Program
Business Wire - Tue Mar 04, 7:01AM CST
Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today that it has been notified by the U.S. Food and Drug Administration (the "FDA"
that the agency has completed its review of the September 2013 nonclinical submission and has lifted the clinical hold on Oxycyte(R). Lifting of the clinical hold clears the company to proceed with the clinical development program in the US. The FDA communicated this information to the company during a conference call with the FDA on Friday, February 28, 2014. Written confirmation of the FDA's decision is expected to be received within 30 days. OXBT: 4.04 (+0.02), EMCI: 33.30 (-0.55)
Research and Markets: Panel Builders Market: Research & Analysis UK 2014-2018
Business Wire - Thu Feb 20, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/5b4nzh/panel_builders) has announced the addition of the "Panel Builders Market: Research & Analysis UK 2014-2018" report to their offering.
OXBT: 4.04 (+0.02)
